Executive Leadership Team

Technow_Oliver

Oliver Technow

Chief Executive Officer
Linkedin-in Envelope Twitter
Oliver's Profile
Ted

Ted Dolan

Chief Operating Officer
Linkedin-in Envelope
Ted's Profile
Peter 3

Peter Ercoli

Chief Operating Officer, Biologics
Linkedin-in Envelope
Peter's Profile
Delage_Heather

Heather Delage

Chief Commercial Officer
Linkedin-in Envelope
Heather's Profile
David L

David Long

Chief Financial Officer
Linkedin-in Envelope
David's Profile
Marc-S

Marc Sauer

Chief Science Officer
Linkedin-in Envelope
Marc's Profile
SCott

Scott Doncaster

Vice President, Strategic Projects
Linkedin-in Envelope
Scott's Profile
Lester

Lester Wood

Vice President, People & Corporate
Culture
Linkedin-in Envelope
Lester's Profile
Valana

Valana Deighan

General Counsel
Envelope
Valana's Profile

Operations Leadership Team

Mark-W

Mark Wellman

Vice President and General Manager, Complex Chemistry Operations

Envelope
Mark's Profile
DeLong_Shawn

Shawn DeLong

Vice President and General Manager, Biologics Operations

 
Linkedin-in Envelope
Shawn's Profile
Peter

Peter Phillips

Vice President, Quality Operations

 
Linkedin-in Envelope
Peter's Profile
Bryan Lowery

Bryan Lowery

Vice President & General Manager, mRNA Vaccine and pDNA Operations (Interim)

Envelope
Bryan's Profile

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors

Ted Dolan - Chief Operating Officer

  • +35 years of operations and executive management experience in the pharmaceutical and CDMO space
  • Responsible for the execution of business objectives and overall operational excellence
  • MBA in Production Management and Finance from Saint Joseph’s University
  • Executive Management, Lean Manufacturing from the University of Michigan
  • Joined BIOVECTRA as Chief Operations Officer in 2021

Peter Ercoli - Chief Operating Officer, Biologics

  • Bachelor of Science in Engineering, US Military Academy at West Point.
  • Captain, US Army (Artillery): Six years active duty in Germany, Oklahoma & Hawaii.
  • Thirty years of progressive responsibility in regulated industry, including: Large Molecule Manufacturing; API Manufacturing; Drug Product, Cosmetics, Nutraceuticals; Pharmaceutical Manufacturing; Diagnostic Lab Operations; Medical Devices; and, Nuclear Power Piping.
  • Executive level experience in Manufacturing Operations, Quality Operations, Supply Chain, Engineering, Finance, and Strategy.
  • Fifteen years of experience as Vice President / General Manager across four companies and six sites.

Heather Delage - Chief Commercial Officer

  • B.B.A., University of Prince Edward Island (1990).
  • Continued Education: McGill Mini-MBA program, York School of Business concentrated courses (Key Account Management, Project Management).
  • 1990-2000: Diagnostic Chemicals Limited – Various roles in sales and marketing management, International distribution and project operations for development and commercialization of clinical diagnostic products for hospital and laboratory markets.
  • 2000-2014: BIOVECTRA – Increasing leadership roles in commercial functions, building a business development team and client base as a specialized global CDMO.
  • Appointed to Vice President, Business Development for BIOVECTRA in 2014.
  • Promoted to Chief Commercial Officer in 2021.

David Long - Chief Financial Officer

  • +30 years of experience in Finance and IT leadership, including the CDMO space
  • Chartered Professional Accountant, CGA
  • MBA in Finance and International Business from Dalhousie University
  • Joined BIOVECTRA as Chief Financial Officer in 2020

Marc Sauer - Vice President & GM, Process Science & Development Services

  • B.Sc. in Organic Chemistry and M.Sc. in Physical Chemistry from the University of Oldenburg, Germany.
  • Worked as a Scientist at Beiersdorf AG, Hamburg, Germany in developing and analyzing Pegylated medical devices.
  • Ph.D. in Physical Chemistry from the University of Basel, Switzerland.
  • Postdoctoral Research (NATO and Swiss National Science Foundation Postdoctoral Fellowship) at the University of British Columbia, Vancouver.
  • Lecturer at the University of British Columbia.
  • Joined BIOVECTRA in 2006 as an Analytical Research Chemist.
  • Took the position of Analytical Research Group Leader in 2007 and Analytical Services Group Leader in 2008 to oversee the Analytical Research and Quality Control groups.
  • Assumed the Manager as Analytical Services in 2010.
  • Promoted to Director of Analytical Services in 2013.
  • Appointed to Vice President, Research & Development in 2014.
  • Appointed Vice President & General Manager, Process Science & Development Services in 2020.

Scott Doncaster - Vice President, Manufacturing, Technology & Engineering

  • B.Sc. in Biochemistry from Mount Allison University in 1990.
  • Worked towards a Masters program in Biochemistry at Queens University from 1991-1994.
  • Worked for the Hunter Group in Aurora, Ontario from 1994-1995 in developing and supervising high purity solvent distillation processes.
  • Joined BIOVECTRA in 1995, supervising the enzyme and natural products bioextraction processes.
  • Promoted to Operations Manager in 2000 and served in that position until 2003.
  • Served as capital project manager for the BIOVECTRA API facility in 2001-2002.
  • Took the position as Director of Operations for Atlantis BioActives in 2003 to oversee the capital installation, start-up and commercial extraction process for natural taxanes.
  • Promoted to Director of Manufacturing for BIOVECTRA in 2005.
  • Appointed to Vice President, Manufacturing Technologies & Engineering in 2014.

Lester Wood

  • BBA from UNB Fredericton (1989).
  • Certified Human Resources Specialist (CHRP).
  • 20 years of Human Resource experience in Professional Service, Health Care, and Oil & Gas.
  • Appointed to Executive Director, Human Resources in 2016.
  • Appointed to Vice President, People & Corporate Culture in 2020.

Valana Deighan - General Counsel

  • B.Sc. Degree from University of Prince Edward Island (2001).
  • LL.B. from University of New Brunswick (2004).
  • Admitted to Prince Edward Island Bar (2005).
  • Joined BIOVECTRA in 2005 as Associate General Counsel.
  • Appointed General Counsel in 2011.
  • Responsible for legal and corporate matters.

Mark Wellman - Vice President and General Manager, Complex Chemistry Operations

  • M.Sc. Degree from Memorial University of Newfoundland in 1996.
  • Over 20 years experience with BIOVECTRA over which time he has contributed as a team member towards the development of fine chemicals, advanced intermediates, and active pharmaceutical ingredients.
  • Held the positions of Research Scientist (1996), Product Manager (2001), Custom Synthesis Project Manager (2003) and Manufacturing Manager, Special Projects (2005). He has participated or successfully led several API manufacturing projects to completion.
  • Promoted to Director of Biotech Operations in 2009.
  • Appointed to Vice President, Manufacturing in 2014.
  • Appointed to Vice President & General Manager, Complex Chemistry in 2020.

Shawn DeLong - Vice President and General Manager, Biologics Operations

  • B.Sc Mechanical Engineering, University of New Brunswick 2007
  • 15 years’ experience in pharmaceutical manufacturing operations
  • 2007-2013 – As Project Engineer managed construction, commissioning, and optimization of medium and commercial scale manufacturing equipment
  • Became the Unit Manager for a commercial manufacturing operation in 2013 and promoted to Director of Commercial Manufacturing in 2015
  • In 2016, added Biotech manufacturing operations to portfolio
  • In 2018, promoted to acting Site Lead of Windsor biomanufacturing facility
  • In 2020, promoted to Vice President & General Manager, Biologics

Peter Phillips - Vice President, Quality Operations

  • Bachelor of Science, Chemistry from the University of Calgary.
  • More than 25 years pharmaceutical experience in QC, QA, and R&D.
  • More than 20 years experience in leading QC and QA teams.
  • In 1997 was appointed Director of QC at Taro Pharmaceuticals, in 2005 was appointed Director QA at Taro Pharmaceuticals and in 2007 was appointed Director Quality (QA/QC) at Ranbaxy Pharmaceuticals.
  • Joined BIOVECTRA in January 2016 as Vice President, Quality Operations

Bryan Lowery - Vice President & General Manager, mRNA Vaccine and pDNA Operations (Interim)

  • BSc in Nuclear Engineering Technology (Thomas Edison College), MSQA (California State University), and MBA (Webster University).
  • Seventeen years of experience in pharmaceutical / biopharmaceuticals sector, including CDMO Manufacturing
  • Twelve years operational leadership experience in manufacturing and CDMO operations
  • Specialization in Change Management and Operations transformational leadership with focus on Lean/Six Sigma
  • Nuclear Engineering Lead Petty Officer and Nuclear Operations Instructor with the US Navy